What changed in this filing

/stocks — the workspaceLOADING

Item 5. Market for Registrant’s Common Equity

2022-03-08 compared with 2021-03-29 · 34 added, 31 removed, 7 unchanged (90% of the section changed)

For Registrant’s Common Equity, Related Stockholder Matters And Issuer Purchases Of Equity Securities

Price and Dividend Information

common stock is quoted on the NYSE American under the symbol “MTNB”.

The following table sets forth the high and low

sales price for our common stock for each full quarterly period within the last two fiscal years, as reported by the NYSE American.

Fiscal Year 2019

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

Fiscal Year 2020

First Quarter

Second Quarter

Third Quarter

Fourth Quarter

March 12, 2021, the closing sale price of our common stock, as reported by the NYSE American, was $1.20 per share and we had approximately

February 25, 2022, the closing sale price of our common stock, as reported by the NYSE MKT, was $0.60 per share and we had approximately

107 record holders of our common stock.

The number of record holders was determined from the records of our transfer agent and

does not include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and

registered clearing agencies.

The number of record holders was determined from the records of our transfer agent and does not

include beneficial owners of common stock whose shares are held in the names of various security brokers, dealers, and registered clearing

VStock Transfer, LLC is the transfer agent and registrar for our common stock.

have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our

common stock in the foreseeable future.

We intend to retain all available funds and any future earnings to fund the development

and expansion of our business.

Any future determination to pay dividends will be at the discretion of our board of directors and

will depend upon a number of factors, including our results of operations, financial condition, future prospects, contractual

restrictions, restrictions imposed by applicable law and other factors our board of directors deems relevant.

have never paid or declared any cash dividends on our common stock, and we do not anticipate paying any cash dividends on our common

stock in the foreseeable future.

We intend to retain all available funds and any future earnings to fund the development and expansion

of our business.

Any future determination to pay dividends will be at the discretion of our board of directors and will depend upon a

number of factors, including our results of operations, financial condition, future prospects, contractual restrictions, restrictions

imposed by applicable law and other factors our board of directors deems relevant.

Sales of Unregistered Securities

February 8, 2022, 400,000 shares of our common stock were issued to Rutgers, The State University of New Jersey (“Rutgers”),

as partial consideration of the Second Amended and Restated Exclusive License Agreement, dated February 8, 2022, between us and Rutgers.

Such shares were issued to Rutgers pursuant to an exemption from the registration requirements of the Securities Act by virtue of Section

4(a)(2) of the Securities Act because we believe:

(i) the securities were offered and sold only to an accredited investor;

and (ii) Rutgers

had knowledge and experience in financial and business matters which allowed it to evaluate the merits and risk of the receipt of these

securities, and that it was knowledgeable about our operations and financial condition.

Further, there was no general solicitation or

general advertising related to this issuance of such shares.

September 3, 2021, 1,500,000 shares of our common stock were issued to the holders of Aquarius Biotechnologies Inc.

as partial consideration of the Amendment, dated September 3, 2021, to the Agreement and Plan of Merger by and among the Company, Saffron

Merger Sub, Inc., Aquarius and J Carl Craft, as holder representative, dated January 19, 2015 (the “Aquarius Merger Agreement”).

Such shares were issued in place of certain milestone payments previously included under the Aquarius Merger Agreement upon the achievement

of specified development milestones.

Such shares were issued to the holders of Aquarius, as defined in the Aquarius Merger Agreement,

pursuant to an exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) of the Securities Act

because we believe:

(i) the securities were offered and sold only to accredited investors;

and (ii) the holders had knowledge and experience

in financial and business matters which allowed each of them to evaluate the merits and risk of the receipt of these securities, and

that each holder was knowledgeable about our operations and financial condition.

Further, there was no general solicitation or general

advertising related to this issuance of such shares.

of Equity Securities by the Issuer and Affiliated Purchasers

did not purchase any of our registered securities during the period covered by this Annual Report.

Financial Data

§229.301 of Regulation S-K, the Company, designated a Smaller Reporting Company as defined in Section §229.10(f)(1)

of Regulation S-K, is not required to provide selected financial data.

Management’s Discussion and Analysis of Financial

Condition and Results of Operations is intended to help the reader understand the results of operations and financial condition

of the Company and should be read in conjunction with our audited consolidated financial statements and notes thereto for the

year ended December 31, 2020.

Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.

What changed 10-K

Item 5. Market for Registrant’s Common Equity